Aspira Women's Health
About: Aspira Womens Health Inc is engaged in developing and commercializing diagnostic tests for gynecologic diseases. Its products include OvaSuite which is a portfolio of blood tests that applies proprietary algorithms incorporating patient features; OvaWatch intended for use in assessing the risk of ovarian cancer for women with adnexal masses; and Ova1Plus is a portfolio of blood tests, Ova1Plus is a combination of two FDA-cleared tests for women with pelvic masses who are planned for surgery.
Employees: 64
0
Funds holding %
of 7,390 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
4% more funds holding
Funds holding: 24 [Q3] → 25 (+1) [Q4]
5.93% less ownership
Funds ownership: 14.67% [Q3] → 8.74% (-5.93%) [Q4]
46% less capital invested
Capital invested by funds: $1.91M [Q3] → $1.03M (-$881K) [Q4]
56% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 9
Research analyst outlook
We haven’t received any recent analyst ratings for AWH.
Financial journalist opinion
Neutral
Accesswire
9 hours ago
Aspira Women's Health Reports Fourth Quarter and Full Year 2024 Financial Results
Record 2024 OvaSuite revenue of $9.2 million and volume of 24,305 units sold AUSTIN, TX / ACCESS Newswire / March 27, 2025 / Aspira Women's Health Inc. ("Aspira" or the "Company") (Nasdaq:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today reported its financial results for the fourth quarter and year ended December 31, 2024. Select financial results are as follows: Fourth Quarter 2024 and Recent Financial Highlights • Product revenue increased 9.5% to $2.3 million for the three months ended December 31, 2024, compared to $2.1 million for the same period in 2023.
Neutral
Accesswire
2 weeks ago
Aspira Women's Health Announces Closing of $1.37 Million Private Placement of Convertible Notes
AUSTIN, TX / ACCESS Newswire / March 11, 2025 / Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that it has entered into a securities purchase agreement dated March 6, 2025, pursuant to which the Company has sold and issued an aggregate principal amount of $1.37 million in the form of Senior Secured Convertible Promissory Notes due March 6, 2030 (the "Convertible Notes") in a private placement (the "Private Placement") with existing and new accredited investors. The Convertible Notes will be a senior, secured obligation of the Company and interest will accrue and be payable quarterly in kind at the applicable federal rate (currently 3.34%).
Neutral
Accesswire
1 month ago
Aspira Women's Health Submits Request for Withdrawal of Form S-1 Registration Statement
Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that it has filed a request for withdrawal with the Securities and Exchange Commission (the "SEC") of the Company's Registration Statement on Form S-1 (No. 333-284182), as amended, originally filed on January 8, 2025 (the "Registration Statement"), as the Company no longer intends to pursue a public offering under the Registration Statement at this time.
Neutral
Accesswire
1 month ago
Aspira Women's Health Announces Appointment of Ellen Beausang to the Board of Directors
AUSTIN, TX / ACCESS Newswire / February 11, 2025 / Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced the appointment of Ellen Beausang to the Board of Directors, effective February 10, 2025. "We are pleased to welcome Ellen Beausang to the Board of Directors," said Michael Buhle, Chief Executive Officer of Aspira Women's Health.
Neutral
Accesswire
2 months ago
Aspira Women's Health Announces the Appointment of Mike Buhle as SVP of Commercial Operations
Interim CFO John Kallassy to Depart January 10 AUSTIN, TX / ACCESSWIRE / January 10, 2025 / Aspira Women's Health Inc. ("Aspira" or the "Company") (Nasdaq:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced the appointment of Mike Buhle as SVP of Commercial Operations. Mr. Buhle has over 25 years of experience driving commercial growth and new product launches in the diagnostics and life science tools domains, working for start-up, scale-up, and established businesses.
Neutral
GlobeNewsWire
3 months ago
Aspira Women's Health Announces Appointment of Dr. Sandra Milligan as Interim CEO
CEO Nicole Sandford will step down for personal reasons and will remain as a consultant to ensure a seamless transition CEO Nicole Sandford will step down for personal reasons and will remain as a consultant to ensure a seamless transition
Neutral
GlobeNewsWire
3 months ago
Aspira Women's Health Successfully Reaches the First Milestone of the ARPA-H $10 Million Award
The Company received the first $2 million from the ARPA-H Sprint for Women's Health Award The Company received the first $2 million from the ARPA-H Sprint for Women's Health Award
Negative
Zacks Investment Research
4 months ago
Aspira (AWH) Reports Q3 Loss, Lags Revenue Estimates
Aspira (AWH) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to loss of $0.48 per share a year ago.
Neutral
Seeking Alpha
4 months ago
Aspira Women's Health Inc. (AWH) Q3 2024 Earnings Call Transcript
Aspira Women's Health Inc. (NASDAQ:AWH ) Q3 2024 Earnings Conference Call November 14, 2024 8:30 AM ET Company Participants Nicole Sandford - Chief Executive Officer & Director Sandy Milligan - President John Kallassy - Interim Chief Financial Officer Conference Call Participants Operator Good morning, ladies and gentlemen and welcome to Aspira Women's Health Incorporated Third Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Neutral
GlobeNewsWire
4 months ago
Aspira Women's Health to Announce Third Quarter Earnings Results and Host a Conference Call on Thursday, November 14, 2024
Management to Announce Earnings Results and hold a call at 8:30 am ET Management to Announce Earnings Results and hold a call at 8:30 am ET
Charts implemented using Lightweight Charts™